Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 244-249

  Li, Li ^a   Pan, Zhongmian ^a   Gao, Kun ^a   Zhang, Wei ^a   Luo, Yuan ^a   Yao, Zhongqiang ^a   Liang, Xinqiang ^a   Tang, Bujian ^a   Li, Qingdi Quentin ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Hormone replacement therapy; Life quality; Ovarian malignancy; Prognosis

Indexed keywords

CALCITONIN; CONJUGATED ESTROGEN; ESTRIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MEDROXYPROGESTERONE; NILESTRIOL; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; OVARY CANCER; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; RADIOIMMUNOASSAY;

EID: 84855218533     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.461     Document Type: Article

References (28)

1. Williams T, Toups KL, Saggese D, et al: Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 6: 2936-2962, 2007.
2. Jacobs IJ and Menon UM: Progress and challenges in screening for early detection of ovarian cancer. Cell Proteomics 3: 355-366, 2004.
3. Mok SC, Kwonga J, Welch WR, et al: Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23: 367-376, 2007.
4. Lawrenson K and Gayther SA: Ovarian cancer: a clinical challenge that needs some basic answers. Plos Med 6: 126-129, 2009.
5. Deraco M, Baratti D, Laterza B, et al: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37: 4-9, 2011.
6. Hopkins ML, Fung MF, Le T, et al: Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 92: 827-832, 2004.
7. Singh P and Oehler MK: Hormone replacement after gynaecological cancer. Maturitas 65: 190-197, 2010.
8. Chikman B, Lavy R, Davidson T, Wassermann I, Sandbank J, Siegelmann-Danieli N and Halevy A: Factors affecting rise in the incidence of infiltrating lobular carcinoma of the breast. Med Assoc J 12: 697-700, 2010.
9. Braem MG, Onland-Moret NC, van den Brandt PA, et al: Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172: 1181-1189, 2010.
10. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L and Wang B: Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108: 641-651, 2008.
11. Hinds L and Price J: Menopause, hormone replacement and gynaecological cancers. Menopause Int 16: 89-93, 2010.
12. Taube M, Hockenstrom T and Isakasson M: Low sex steroid environment affects survival and steroid secretion of ovarian tumor cell in primary cultures. Int J Oncol 20: 589-594, 2002.
13. Mabuchi S, Ohmichi M, Kimura A, et al: Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. Endocrinology 145: 49-58, 2004.
14. Seeger H and Mueck AO: The effect of estradiol metabolites and progestogens on the proliferation of human ovarian cancer cells. Panminerva Med 48: 13-17, 2006.
15. Zheng H, Kavanagh JJ and Hu W: Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17: 325-330, 2007.
16. Levgur M: Estrogen and combined hormone therapy for women after genital malignancies. J Reprod Med 49: 837-848, 2004.
17. Aaronson NF, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
18. Zhong-Mian P, Li L, Xinqiu C, et al: Effect of HRT for the quality of life in patients with gynecologic malignancies of reproductive age. Guangxi Yikedaxue Xuebao 23: 921-923, 2006.
19. Eeles RA, Tan S, Wiltshaw E, et al: Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302: 259-262, 1991.
20. Li L, Gao K, Zhang W, et al: Effects of estradiol and progesterone on ovarian cancer cell line. Zhonghua Zhongliu Zazhi 25: 553-554, 2003.
21. Landon SP, Crew AJ, Ritchie AA, et al: Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by antioestrogens in vitro and in a xenograft model. Eur J Cancer 30A: 682-686, 1994.
22. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al: Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 78: 302-308, 2000.
23. Biglia N, Mariani L, Marenco D, et al: Hormonal replacement therapy after gynaecological cancer. Gynakol Geburtshilfliche Rundsch 46: 191-196, 2006.
24. Biglia N, Gadducci A, Ponzone R, et al: Hormone replacement therapy in cancer survivors. Maturitas 48: 333-346, 2004.
25. Wenzel LB, Huang HQ, Armstrong DK, et al: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437-443, 2007.
26. Ponzone R, Biglia N, Jacomuzzi ME, et al: Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41: 2673-2681, 2005.
27. Bebar S and Ursic-Vrscaj M: Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 21: 192-196, 2000.
28. Ursic-Vrscaj M, Bebar S and Zakelj MP: Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 8: 70-75, 2001.